Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06716047 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions

Study acronym: probiotics
StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Not applicable to Early Phase 1 Start date: Dec 1, 2023 to Dec 5, 2024 · Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 80 to confirmed 30 · 5 morev2 Show 8 more changesShow less
    • Start date: Dec 1, 2023 to Dec 5, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 80 to confirmed 30
    • Primary completion date changed from estimate of Jul 1, 2025 to Jun 25, 2025
    • Completion date: Aug 1, 2025 to Dec 30, 2025
    • Eligibility criteria shortened, about 33 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We have discovered a type of probiotic that can target activating intestinal NOD2, which is related to a series of human health issues.
Trial Details
NCT Number NCT06716047
Lead Sponsor Zhujiang Hospital
Conditions Microecological Therapy, Probiotic Intervention
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov